Drug and vaccine authorizations for COVID-19: List of applications received

Date published: 2021-02-26

Under the interim order, a company can submit an application for a drug or vaccine for use in COVID-19 that:

An applicant can also file a new drug submission under the Food and Drug Regulations.

The list below includes all applications received by Health Canada for drugs and vaccines used for the COVID-19 pandemic. This list includes applications received under the interim order and those received under the Food and Drug Regulations. The current status of each application is also noted.

Information for each application includes the:

In the "outcome of application" column, there are 4 possible scenarios:

Consult the Drug and health product submissions under review (SUR) list and the Generic submissions under review list to access submissions under review that are not related to the COVID-19 pandemic.

Applications received related to the COVID-19 pandemic
Applicant Medicinal ingredient(s) Therapeutic area Date application was received Outcome of application Date of decision/outcome
Footnote *

This product is approved in Canada for other uses.

Return to footnote * referrer

AstraZeneca Canada Inc Adenovirus vaccine vector (ChAdOx1-S [recombinant]) Vaccines, for human use 2020-10-01 Authorized (with terms and conditions) 2021-02-26
Eli Lilly Canada Inc Bamlanivimab (LY-CoV555) Immune sera and immunoglobulins, for human use 2020-10-12 Authorized (with terms and conditions) 2020-11-20
Gilead Sciences Canada Inc Remdesivir Antivirals for systemic use, for human use 2020-06-19 Authorized (with conditions) 2020-07-27
Moderna Therapeutics Inc mRNA-1273
SARS-CoV-2
Vaccines, for human use 2020-10-12 Authorized (with terms and conditions) 2020-12-23
Pfizer Canada ULC/BioNTech SE Tozinameran (mRNA vaccine, BNT162b2) Vaccines, for human use 2020-10-09 Authorized (with terms and conditions) 2020-12-09
Janssen Inc JNJ-78436735/Ad26.COV2.S Vaccines, for human use 2020-11-30 Under review n/a
Dr Reddys Laboratories Ltd Favipiravir Antivirals for systemic use, for human use 2020-12-18 Under review n/a
Pendopharm Division of Pharmascience Inc ColchicineFootnote * Antigout preparations, for human use 2021-01-25 Under review n/a
Verity Pharmaceuticals Inc/Serum Institute of India (in partnership with AstraZeneca Canada Inc) Adenovirus vaccine vector
(ChAdOx1-S [recombinant])
Vaccines, for human use 2021-01-23 Authorized (with terms and conditions) 2021-02-26
Novavax Inc. NVX-CoV2373 Vaccines, for human use 2021-01-29 Under review n/a
Eli Lilly Canada Inc Bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) Immune sera and immunoglobulins, for human use 2021-02-16 Under review n/a
Hoffmann-La Roche Limited Casirivimab and imdevimab Immune sera and immunoglobulins, for human use 2021-02-24 Under review n/a
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: